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Abstract:
This study aims to identify potential discrepancies between the racial/ethnic demographics of
participants enrolled in randomized controlled trials of antibacterials used to treat Staphylococcus aureus
and the demographics for those who contract the disease. 115 clinical trials were analyzed for gender,
racial, and ethnicity of clinical trial participants. Of the included studies, 95.7% included data on gender,
71.3% included racial data, and 27.0% included ethnicity data. Black/African American individuals were
substantially underrepresented in trials when compared to the burden of disease that they share.
Black/African American representation in S. aureus clinical trials needs to be ensured in order to properly
investigate clinical efficacy of new antibiotics. Ethnicity data should be gathered by researchers on all
clinical trials. A standard reporting method for race/ethnicity needs to be implemented for clinical trials to
ensure comparability and to allow for analysis on more specific racial/ethnic groups.
Key words: Staphylococcus aureus, racial groups, ethnicity, anti-bacterial agents, clinical trials
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Introduction:
The importance of representation in clinical trials cannot be overstated. Disparities in morbidity
and mortality by race can be found in the United States even after controlling for socioeconomic and
treatment differences.1 The United States is in need of new antibiotics to treat infections due to antibiotic
resistant pathogens, however, recent research on cancer and heart disease clinical trials has shown that
trial participants are not representative of the populations that are impacted by the disease.2,3 Research
also shows that members of different sexes, races and ethnicities may respond differently to treatments. 4-6
No prior research into the demographics of current antibacterial clinical trial participants exist.
Staphylococcus aureus is a bacteria that can asymptomatically colonize humans and also lead to
infection, commonly referred to as a “staph” infection.7 Methicillin-resistant S. aureus (MRSA) infections
are difficult to treat because of resistance to antibiotics. Methicillin susceptible S. aureus (MSSA), like
MRSA, can be deadly but differ as they are susceptible to treatment using antibiotics. MRSA and MSSA
can cause a range of infections including pneumonia, bloodstream and surgical site infections.8 In 2019,
the Center for Disease Control and Prevention (CDC) announced that MRSA was categorized as a
“serious risk”, the second highest risk category, in their Antibiotic Resistance Threats in the United States
publication.9 The same report estimated 323,700 MRSA cases in hospitalized patients and 10,600 deaths
in 2017.
This study aims to identify potential discrepancies between the racial/ethnic demographics of
participants enrolled in randomized controlled trials of antibacterials used to treat MSSA and MRSA
including those with skin and soft tissue infections (SSTI), bloodstream infections, and pneumonia caused
by S. aureus in the United States and those traditionally infected with the bacteria. Over 100 clinical trials
were analyzed for participant demographics and compared to the demographics of those afflicted with
MRSA using a participant to prevalence ratio.
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Methods:
This paper was designed to investigate the proportion of S. aureus clinical trials reporting gender,
race, and ethnicity of trial participants and investigate whether these trials accurate represent the burden S.
aureus has in the United States.
Papers were collected using Covidence in order to facilitate systematic review management. Two
databases were searched, the “Cochrane CENTRAL” database, which includes PubMed, Embase,
CT.gov, ICTRP, and CINAHL and the U.S. National Library of Medicine’s ClinicalTrials.gov database.
The following search strategy was used for Cochrane CENTRAL:
1) One of the following:
-MeSH descriptor: [Anti-Bacterial Agents] OR
-MeSH descriptor: [Anti-Infective Agents] OR
-“anti-infective” OR antimicrobial OR antimicrobials OR antimicrobially OR
“antimicrobial” OR “anti-bacterial” OR antibiotic OR antibiotics OR
“antibiotic’s” OR antibiotical OR antiinfective OR antiinfectives OR
antiinfection OR antibacterial OR bacteriocide OR bacteriocides OR
antibacterials OR antibacterially
2) And one of the following:
-MeSH descriptor: [Staphylococcal Infections] OR
-MeSH descriptor: [Staphylococcus aureus] OR
-“Staphylococcus aureus” OR “Methicillin-resistant Staphylococcus aureus” OR MRSA
3) And publication year from 2000 to 2021, in Trials
4) And publication year from 2000 to 2021, in Trials (Word variations have been searched)
This search criteria resulted in 1,790 results.
The following search strategy was used for ClinicalTrials.gov:
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1) Other terms:
“anti-infective” OR antimicrobial OR antimicrobials OR “antimicrobial” OR “antibacterial” OR antibiotic OR antibiotics OR antiinfective OR anttinfectives OR
antibacterial OR bacteriocide OR bacteriocides OR antibacterials OR antibacteriocides
2) And condition or disease:
“Staphylococcus aureus” OR “Methicillin-resistant Staphylococcus aureus” or MRSA
3) And recruitment status:
Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation,
Suspended, Terminated, Unknown status Studies
4) And country:
United States
5) And first posted:
1/1/2000 to 12/31/2021
Each study’s abstract was analyzed to ensure the scope of the study fell under the auspices of this
literature review. Excluded studies included:
-Animal studies
-Studies of nonbacterial infections
-Interventions/trials of substances that do not have direct anti-bacterial activity (e.g., honey, tea
tree oil)
-Studies not published in English
-International studies with no patients in the United States
-Conference abstracts, book chapters, case studies or case series, editorials, letters, preprints,
review articles, systematic reviews
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-Studies of antibiotic stewardship
-Studies of antibiotic prophylaxis (e.g., for surgery or in cystic fibrosis patients)
-Cost-effectiveness studies
-Studies including diagnostic devices
-Intra-abdominal infections
-Upper gastrointestinal perforations
-Nasal colonization or decolonization studies
-Studies of nasal carriage
-Studies about mupirocin
-Studies of essential oils (e.g., tea tree oil)
-Perforation caused by surgical error
-Studies of probiotics
-Topical antibiotics
-Pharmacokinetic-Pharmacodynamic (PK/PD) studies
-MIC and molecular epidemiology studies
-Otitis media
-Exclude but flagged (articles of interest)
This search criteria resulted in 1,893 results (Figure 1). There were 56 duplicate studies found and
removed. Each study’s title and abstract were reviewed for relevance to the research question which
resulted in the removal of 1,489 studies that did not meet our criteria. Full text review removed 267
articles resulting in a final 115 studies to be included in this literature review.
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After full text review, a Qualtrics database was created for extraction of relevant data. Trial
participants were categorized based on the published papers. Data extracted for each study included
participant’s age, gender, ethnicity, and race. For age, participants were classified as “adult” (>= 18) or
pediatric (<=17). With regards to gender, participants were classified as “male”, “female”, or “nonbinary”. The race of participants was designated to the following categories: Black, White, Asian, Native
(including Native American, Native Alaskan, and Native Hawaiian), Multiracial, Unknown, and Other.
When a given racial breakdown was not consistent with this study’s, the most similar classification was
used (e.g. Navajo nation was classified as Native American). Finally, the ethnicity of participants was
classified as “Hispanic”, “non-Hispanic”, or “unknown Hispanic”. Because some studies did not include
gender, racial, or ethnicity breakdowns the total number of participants for which data is available
changes by how the data is broken down.
Study characteristics were also recorded, including funder (academic, industry, or both), trial
phase (1, 2, 3, 4, post-licensure, or unknown), and infection type (bloodstream infections (BSI),
respiratory tract infections, acute bacterial skin and skin structure infections (ABSSIs), bone/joint
infection, or other). If the infection type was a respiratory tract infection, the type of infection was also
recorded as ventilator-associated pneumonia (VAP), hospital-associated pneumonia (HAP), or
community-associated pneumonia (CAP). The entity (or entities) that sponsored each trial was also
collected; sponsors were classified as either academic or industry. Included studies were coded as
including pediatric patients if they included any participants under the age of 18 (non-inclusive) and adult
patients if the study included participants over 18 years old (inclusive).
In order to accurately compare trial participant demographics to the demographics of the
population experiencing MRSA and MSSA infections, incidence rates and racial demographics were
extracted from 15 years of CDC MRSA report data (2005-2019) and three years of CDC MSSA report
data (2016-2019).11-25 To compare MRSA rates to national demographics, race and ethnicity estimates
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were taken from the United States Census Bureau.26 Four studies were found that estimated the burden of
S. aureus by gender (Table 1).27-30
We calculated the proportion of male participants, White participants, Black participants, and
Hispanic participants for each study. Participant to prevalence ratios (PPRs) were calculated as described
by Poon and Varma10-11) by dividing the percentage of study participants in each demographic group by
the percentage of the MRSA population in each group. Underrepresentation was defined as a PPR less
than 0.8. Overrepresentation was defined as PPR over 1.2. Prevalence was estimated using CDC reporting
statistics. Since CDC reporting was not available for Hispanic/Latino populations, census data was used
and the prevalence of Hispanic/Latino individuals in the United States was used as the estimate for
Hispanic/Latino burden of MRSA.

Results:
After extraction and full text review, 115 studies were included in the analysis. An overwhelming
majority of studies (n=110, 95.7%) included the gender of all participants. Only 82 of the evaluated
studies (71.3%) included the race of participants. Thirty-one studies (27.0%) included ethnicity data for
participants (Table 2).
When pooling all the studies that supplied gender data, the total number of clinical trial
participants was 48,461. Of those, 29,247 (60.4%) identified as male and 19,214 (39.6%) identified as
female. No study indicated that participants identified as or were given an option to indicate as any other
gender identity (Table 3).
The minimum proportion of men in a given study was 0.36, the maximum proportion was 0.99,
with a mean proportion of 0.61 and a standard deviation of .08. Most studies were adequately
representative of gender (n=97, 88%). The minimum proportion of White individuals was 0 and a
maximum proportion of .99. The mean and standard deviation (SD) proportion of White individuals was
0.69 SD 0.22. The mean proportion of White participants was significantly higher when compared to the
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mean proportion of White individuals with MRSA as reported by the CDC (p<0.01). A majority of
studies overrepresented white individuals (n=45, 57%; Table 4). Only 6 studies (7%) had adequate
representation for Black/African American individuals; in 87% of studies (n=71) this population was
underrepresented (Table 4).
The range of Hispanic or Latino individuals in a study was 0.04-0.34 with a mean of 0.17 SD
0.1. Hispanic/Latino populations were often underrepresented (n= 15, 48%), but in 32% (n=10) of studies
analyzed they were also overrepresented (Table 4).
The earliest any included study began enrolling participants was in June of 1995, while the most
recent data collected by any study was in April of 2019. Academic sponsors included the National
Institutes of Health (NIH), universities, and university-associated healthcare systems (Table 5). Only 13
studies (11.3%) included exclusively pediatric patients. Most studies (n=87, 75.7%) included exclusively
adult patients. Studies that included both pediatric and adult populations totaled 14 and represented 12.2%
of all studies. One study (0.9%) did not indicate the age of participants (Table 5).
The CDC data shows that over the last 15 years, approximately 60% of MRSA cases are among
White identifying individuals, 36% are Black identifying individuals, and 4% are by other race
identifying individuals. CDC data also shows that the number of MRSA cases has been declining since
2005 but shifted to a small upward trend since 2015 (Table 6). Although limited, the MSSA data supplied
by the CDC shows that a much larger proportion of other races experience infection due to MSSA (Table
7). Data also shows a steady increase in MSSA cases since the data became available (Table 7).
Prevalence ratios are provided in Table 9.
Importantly, the CDC also publishes incidence rate information. Data collected showed a steep
decline in MRSA incidence rates among the black population, dropping from 78.3 cases per 100,000
individuals in 2005 to 29.5 cases per 100,000 individuals in 2019 (a 62% decline). Comparatively smaller
declines were experienced by the white and other racial incidence rates, falling from 29.9 cases per
100,000 individuals in 2005 to 21.2 cases per 100,000 individuals in 2019 for whites (a 29% decline) and
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from 12.9 cases per 100,000 individuals in 2005 to 7.3 cases per 100,000 individuals in 2019 for other
races (a 43% decline). Incidence rate data for MSSA was only available for the years 2016 through 2019
(inclusive), however both white and black populations experienced a rise in MSSA incidence rates during
that time period (an 18% and 6% increase for white and black populations, respectively). Only members
of other races experienced a decline in MSSA cases throughout the four-year time period, from 31.3 cases
per 100,000 individuals in 2016 to 24.8 cases per 100,000 individuals in 2019 (a 21% decline) (Tables 89).
There was a significantly higher White population in studies that included international
participants (F=.412, p=.032).

Discussion:
In this study, 115 clinical trials for antibiotics to treat S. aureus infections were analyzed for their
gender, race, and ethnic representation. This study shows that Black/African American individuals are not
adequately represented in clinical trials for S. aureus. It is also evident that better race and ethnicity
reporting needs to be implemented to ensure comparability between studies. Hispanic/Latino populations
were often over- and underrepresented indicating that more time and focus needs to be placed on ensuring
these populations are accurately reflected in clinical trial participants.
There is a clear need to improve racial and ethnicity reporting in relation to clinical trials. A mere
27% of all S. aureus reporting ethnicity. Over a quarter of studies did not publish data related to race of
clinical trial participants.
There is much credit to studies that indicate race/ethnicity should not be a data point collected or
considered in medicine as it stems from the centuries of racism in the medical field.29 There is a vast
body of literature shedding light on the racial bias that still exist in medicine.30 This study does not intend
to contribute or contradict any of these arguments, rather is meant to ensure that clinical trials include
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people of all identities as a comment on American social cohesiveness and represents those that
experience this disease.
While a majority of trials were considered reasonably representative by these parameters, the
pooled demographic data for all included clinical trials shows that this is not the whole story. It is
interesting to note that members of “other” races may actually be overrepresented in clinical trials. While
pooled statistics show roughly 14% participation in clinical trials for non-White and non-Black
individuals, CDC data reports 5% of the MRSA and 10% of the MSSA burden is experienced by this
population.
A vast majority of studies included gender information when reporting their clinical trial results.
Over half of the studies were adequately representative when analyzing PPRs and the pooled
demographics from all included clinical trials fell within the range published by previous investigations
(Table 9). This is important since for much of history medicine was male-centric and focused exclusively
on the efficacy of medicine in men.31
While MRSA cases have substantially dropped since 2005, there has been a concerning increase
since 2015. There has been a substantial drop in incidence rates per 100,000 individuals for the entire
period. While the gap between White incidence rates and Black/African Americans has decreased
extensively, there is clearly still work to be done. There has been a concerning increase in MSSA
incidence among White and Black/African American individuals as shown in the CDC MSSA data.
While the total number of MSSA cases has been increasing steadily, it is important to note that the MSSA
incidence for “Other races” has been decreasing for the entirety of time data is available. While the rise in
cases and incidence is of great concern, an advantage is the far lower mortality rate for MSSA cases
compared to MRSA.32 This also could be a result of the focus on antimicrobial resistance around the
world.
It would be worthwhile to begin collecting S. aureus data in a different way. Currently the CDC
only supplies racial data for three racial groups (Tables 6-9) and for no ethnic groups. It would be
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worthwhile to create a template for all clinical trials to collect the same racial/ethnic data among all
clinical trials to ensure proper representation and to prevent any miscommunications or errors in data
collection. This standardization would be helpful for current research to ensure compliance and efficacy
data is comparable across clinical trials. It will also allow future researchers to find new uses and
information concerning a given drug by other racial/ethnic groups should it be needed at a later time. The
current method is incompatible to determine potential issues or uses among other racial/ethnic groups.
Having a more specific racial breakdown could allow for more particular recommendations on
representation for clinical trials. For example, Native American populations may compose most “Other
Race” S. aureus, yet only account for .04% of clinical trial participants. While current data suggests
“Other Race” participants are adequately represented, standardized data collection and reporting methods
may allow for more particular focuses to be needed.

Limitations:
As with most studies, there is always the limitation of human error; with several data checks there
are still concerns that the extracted data may have in some way be entered inconsistently or with mistakes.
There is also the inherent concern in meta-analysis that the papers examined were in some way flawed or
that the search criteria were in some way non-inclusive of all papers with pertinent data to the topic.
Unique to this study is the possibility that there are better ways to investigate “reasonable representation”
in a given study. A final limitation is the inability to break down beyond three racial groups. CDC data
does not report MRSA or MSSA cases outside of these three categories. Many clinical trials that were
analyzed follow this pattern. Due to this, it is impossible to estimate the true burden or representation in
clinical trials of S. aureus on racial groups outside of “White/Caucasian”, “Black/African American” and
“Other”.
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Conclusion:
Black/African American representation in S. aureus clinical trials needs to be ensured in order to
properly investigate clinical efficacy of new antibiotics. Ethnicity data needs to be gathered by
researchers on all clinical trials. A standard reporting method for race/ethnicity needs to be implemented
for clinical trials to ensure comparability and to allow for analysis on more specific racial/ethnic groups.
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Appendix A: Figures

Figure 1: Flow of papers through the PRISMA process

Figure 1 shows where in each step of the review process a given study was removed.

Figure 2 shows the trends over time of MRSA and MSSA incidence rates by a given race.
The incidence rates for MSSA are shown in yellow, orange, and green, while the
incidence rates for MRSA are shown in light blue, dark blue, and gray. Each value is the
incidence rate per 100,000 individuals.
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Appendix B: Tables

Table 1: Gender/Sex of samples from studies estimating the burden of S. aureus
Study Title

Trends in Invasive
Infection with
MethicillinResistant
Staphylococcus
aureus,
Connecticut,
USA, 2001-201027

Socioeconomic
Factors Explain
Racial Disparities
in Invasive
CommunityAssociated
MethicillinResistant
Staphylococcus
aureus
Disease Rates28

Public Health
Importance of
Invasive
Methicillinsensitive
Staphylococcus
aureus Infections:
Surveillance in 8
US Counties, 201629

National Burden
of Invasive
MethicillinResistant
Staphylococcus
aureus Infections,
United States,
201130

Study First
Author Last
Name

Hadler

See

Jackson

Dantes

Study
Publication
Year

2012

2017

2020

2013

Male

60.4%

63.5%

61.4%

60%

Female

39.6%

36.5%

38.6%

40%

Table 2: Demographic breakdown in clinical trials
n (%)
Studies that include gender breakdown

115 (100)
110 (96)

Studies that include race breakdown

82 (71)

Studies that include ethnicity breakdown

21 (27)
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Table 3: Pooled participant demographics
Demographic:

n (%)

Number of participants for which gender data was available

48,461 (100)

Male 29,247 (60.4)
Female 19,214 (39.6)
Number of participants for which race data was available
Black/African American

38,387 (100)
5,724 (14.7)

White/Caucasian 27,559 (71.0)
Asian

2,400 (6.2)

Native American/Native Hawaiian/Native Alaskan

165 (0.4)

Multi-racial

330 (0.8)

Unknown race

730 (1.9)

Other race

1,929 (5.0)

Number of participants for which ethnicity data was available

15,659 (100)

Hispanic/Latino

2,879 (18.4)

Non-Hispanic/Non-Latino 12,780 (81.6)

Table 4: Calculated patient to prevalence ratios (PPRS)
PPR for Males
# of studies for which male proportion was calculated

110

# of studies with accurate male participation – n (%)

97 (88)

# of studies where males are underrepresented – n (%)

6 (6)

# of studies where males are overrepresented - n (%)

7 (6)

PPR Min – Max

.59 - 1.62

# of studies for which White proportion was calculated

79

# of studies with accurate White participation – n (%)

27 (34)

# of studies where Whites are underrepresented – n (%)

7 (9)

PPR for Whites/Caucasians
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# of studies where Whites are overrepresented - n (%)

45 (57)

PPR Min – Max

.50 – 1.62

# of studies for which Black proportion was calculated

82

# of studies with accurate Black participation – n (%)

6 (7)

# of studies where Blacks are underrepresented – n (%)

71 (87)

# of studies where Blacks are overrepresented - n (%)

5 (6)

PPR Min – Max

.00 – 2.11

# of studies for which Hispanic proportion was calculated

31

# of studies with accurate Hispanic participation – n (%)

6 (19)

# of studies where Hispanics are underrepresented – n (%)

15 (48)

# of studies where Hispanics are overrepresented - n (%)

10 (32)

PPR Min – Max

.20 – 1.82

PPR for Blacks/African Americans

PPR for Hispanic/Latino

Table 5: Characteristics of S. aureus clinical trials
n

115

Publication Year Range

2000-2021

Study Data Collection
Earliest

06/1995

Latest

04/2019

U.S. Only

62 (54)

U.S. and International

53

Study Location - n (%)

Study Location Type – n (%)
Single-Center

20 (17)

Multi-Center

95 (83)
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Phase – n (%)
1

2 (2)

2

28 (24)

3

32 (28)

Post-Licensure

18 (16)

Not Given

35 (30)

Academic

21 (18)

Industry

83 (72)

Academic & Industry

11 (10)

Trial Sponsor – n (%)

Placebo Controlled? – n (%)
Yes

15 (13)

No

100 (87)

Disease Studied – n (%)
BSI

9 (8)

ABSSIs

73 (63)

Pneumonia

22 (19)
VAP

2 (2)

CAP

9 (8)

HAP

6 (5)

Multiple Types

5 (4)

Bone/Joint Infections

3 (3)

Other

8 (7)

Age Groups – n (%)
Pediatric Only

13 (11)

Adult Only

87 (76)

Multiple Age Groups

14 (12)

Not Given

1 (1)
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Table 6: CDC reported cases of MRSA by race and year11-25
White - n (%)

Black – n (%)

Other – n (%)

Total

2005

3,578 (58)

2,364 (39)

192 (3)

6,134

2006

3,136 (57)

2,128 (39)

202 (4)

5,466

2007

3,408 (60)

2,109 (37)

179 (3)

5,696

2008

3,375 (59)

2,068 (36)

232 (5)

5,675

2009

3,301 (59)

2,067 (37)

237 (4)

5,605

2010

3,034 (61)

1,773 (36)

187 (3)

4,994

2011

2,743 (62)

1,542 (35)

126 (3)

4,411

2012

2,869 (63)

1,554 (34)

159 (3)

4,582

2013

2,843 (62)

1,563 (34)

170 (4)

4,576

2014

2,842 (64)

1,466 (33)

142 (3)

4,450

2015

1,665 (62)

919 (34)

121 (4)

2,705

2016

1,972 (61)

1,134 (35)

108 (4)

3,214

2017

1,960 (59)

1,161 (35)

198 (6)

3,319

2018

2,073 (62)

1,170 (35)

148 (3)

3,319

2019

2,134 (62)

1,148 (33)

155 (5)

3,437

Table 7: CDC reported cases of MSSA by race and year22-25
White - n (%)

Black - n (%)

Other - n (%)

Total

2016

1,551 (63)

584 (24)

311 (13)

2,446

2017

2,254 (66)

858 (25)

314 (9)

3,426

2018

2,344 (63)

1,024 (27)

380 (10)

3,748

2019

2,396 (63)

984 (25.9)

420 (11.1)

3,800
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Table 8: CDC MRSA incidence rate per 100,000 individuals by race and year11-25
White

Black

Other

2005

29.9

78.3

12.9

2006

29.9

70.5

12

2007

27.8

66.6

11.5

2008

25.4

62.1

13.8

2009

23.7

57.6

13.3

2010

22.5

48.2

9.5

2011

20.1

41.5

6.2

2012

20.9

40.9

7.6

2013

20.6

40.6

7.9

2014

20.4

37.4

6.3

2015

17.7

29.9

6.4

2016

19.5

30

5.4

2017

19.3

30

9.5

2018

20.5

30.3

7.1

2019

21.2

29.5

7.3
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Table 9: CDC MSSA incidence rate per 100,000 individuals by race and year22-25
2016

2017

2018

2019

White

31.2

35.2

36.7

36.9

Black

41.5

38.7

46.0

44.1

Other

31.3

19.0

22.7

24.8

Table 10: U.S. 2020 census data by race26
Total individuals

331,449,281

Racial Demographics
% White

76.3

% Black

13.4

% Other

10.3

Ethnic Demographics
% Hispanic/Latino

18.5

% Non-Hispanic/Non-Latino

60.1
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